Unlock instant, AI-driven research and patent intelligence for your innovation.

Pulmonary fibrosis treatment agent, ptprr expression-promoting agent, and kit for pulmonary fibrosis treatment

An expression enhancer, pulmonary fibrosis technology, applied in the field of pulmonary fibrosis therapeutic agents, can solve the problems of IPF patients not receiving treatment effect, insufficient donors, inability and so on

Pending Publication Date: 2019-08-16
ROHTO PHARM CO LTD +1
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the "bleomycin model" does not necessarily correspond to the pathology of pulmonary fibrosis, and pirfenidone and nintedanib have only confirmed the effect of suppressing the exacerbation of the disease
In addition, it is reported that in clinical trials using drugs that have shown effectiveness in the "bleomycin model", almost all IPF patients do not obtain effective therapeutic effects (non-patent literature 2), although in the "bleomycin model" Although the therapeutic effect on lung diseases was confirmed in the "model", it cannot be said that the therapeutic effect on pulmonary fibrosis was actually confirmed.
In addition, there is lung transplantation as a treatment method for pulmonary fibrosis, but there is a shortage of donors and rejection after transplantation is also a problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pulmonary fibrosis treatment agent, ptprr expression-promoting agent, and kit for pulmonary fibrosis treatment
  • Pulmonary fibrosis treatment agent, ptprr expression-promoting agent, and kit for pulmonary fibrosis treatment
  • Pulmonary fibrosis treatment agent, ptprr expression-promoting agent, and kit for pulmonary fibrosis treatment

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0046] (Method for preparing mesenchymal stem cells)

[0047] Mesenchymal stem cells can be prepared by methods known to those skilled in the art. The method for preparing adipose tissue-derived mesenchymal stem cells will be described below as an example. Adipose tissue-derived mesenchymal stem cells can be obtained by, for example, the production method described in US Patent No. 6,777,231, for example, can be produced by a method including the following steps (i) to (iii):

[0048] (i) a process of obtaining a cell suspension by enzymatically digesting adipose tissue;

[0049] (ii) a process of pelleting the cells and resuspending the cells in a suitable medium; and

[0050] (iii) A step of culturing cells on a solid surface and removing cells that do not appear to be bound to the solid surface.

[0051] The adipose tissue used in the step (i) is preferably washed adipose tissue. Washing can be performed by using a physiologically acceptable saline solution (such as pho...

Embodiment 1

[0100] Serum-free medium for mesenchymal stem cells (Rohto) was added to commercially available cells (PT-5006 manufactured by Lonza), and 400 g of the cell suspension was centrifuged for 5 minutes, and the supernatant was removed, and then suspended in mesenchymal stem cells. Cells were inoculated into flasks using serum-free medium (Rohto Company) for mesenchymal stem cells. Incubate the cells at 37°C, 5% CO 2 subculture for several days. Several days later, the culture was washed with PBS to remove blood cells and adipose tissue residues contained in the culture medium, and mesenchymal stem cells adhered to the plastic container were obtained.

[0101] The obtained adipose tissue-derived mesenchymal stem cells were dispensed into centrifuge tubes, and centrifuged at 800 g for 5 minutes to obtain cell pellets. After removing the supernatant, an appropriate amount of cell cryopreservation solution (STEM-CELLBANKER (Zenoaq)) was added for suspension. This cell suspension so...

Embodiment 2

[0103]Specimens were collected from cases in which pulmonary fibrotic lesions were indicated and underwent surgery due to lung cancer. The parts where no fibrosis was observed (fibrosis (-)) and the parts where fibrosis was observed (fibrosis (+)) were separated and the tissues were minced separately, and the DMEM medium (manufactured by Wako Co., Ltd.) supplemented with 15% serum was used to separate the ) at 37°C, 10% CO 2 Culture was started in 1, 1, 2, 4, and 7 days, and the medium was replaced after washing with PBS (manufactured by Wako Co., Ltd.), and cultured for a total of 10 days to obtain UIP (Usual interstitial pneumonia; Usual Interstitial Pneumonia) patients. Lung fibroblasts (hereinafter referred to as "UIP cells").

[0104] UIP cells (5.0 × 10 4 cells / well) were seeded into each well of a 24-well plate in CO 2 Incubator (37°C, 10% CO 2 ) overnight, and the culture medium was replaced with DMEM medium supplemented with 1% serum. The above subcultured and cr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a novel treatment agent for pulmonary fibrosis for which there is currently no effective drug therapy established. The present invention is a pulmonary fibrosis treatment agent containing mesenchymal stem cells. The pulmonary fibrosis is preferably usual interstitial pneumonia (UIP) or idiopathic pulmonary fibrosis (IPF). Also, the mesenchymal stem cells are preferably derived from adipose tissue or are allogeneic.

Description

technical field [0001] The invention relates to a therapeutic agent for pulmonary fibrosis, a PTPRR expression promoter and a kit for treating pulmonary fibrosis. Background technique [0002] Idiopathic interstitial pneumonia (IIP) refers to a group of unexplained interstitial pneumonia diseases with similar clinical features, which can be divided into 6 subtypes according to histological type. All subtypes share, to varying degrees, features of inflammation and fibrosis, all causing dyspnea and typical X-ray abnormalities. The 6 tissue-based subtypes of idiopathic interstitial pneumonia are, in descending order of frequency, common interstitial pneumonia (UIP), nonspecific interstitial pneumonia, bronchiolitis obliterans with pneumonia, respiratory bronchiolitis with interstitial lung disease (ILD), desquamative interstitial pneumonia, and acute interstitial pneumonia. [0003] Idiopathic pulmonary fibrosis (IPF, idiopathic fibrosing alveolitis) is the same as UIP mentio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61K45/00A61P11/00A61P43/00
CPCA61K35/28A61P11/00A61P43/00
Inventor 古野哲生伊藤利洋木村弘吉川雅则泽田牧子
Owner ROHTO PHARM CO LTD